Sindhu Hospitals launches BeyondA1C frontline screening for Diabetic complications in India

HYDERABAD: Sindhu Hospitals, an initiative of Sai Sindhu Foundation, and BeyondA1C, a division of MedicaMetrix, Inc., today signed a Memorandum of Understanding to launch BeyondA1C testing at Sindhu Hospitals. The Sheffield One-Stop becomes its frontline mass screening test for diabetic complications, and regular BeyondA1C testing and could become a potential model for diabetic, dialysis and chemotherapy patients, in the first launch of these tests in India.

Diabetes quietly damages the body’s smallest blood vessels, affecting the nerves, kidneys, eyes and feet. Up to half of people with diabetic nerve damage have no symptoms when it is found, and some estimates put the share left undiagnosed in well-developed health systems at up to 80 percent.

The AI enabled device can deliver testing for 3 key clinical scenarios.

♦ Sheffield One-Stop: A screening test for people at risk of diabetes and suffering from established diabetes - assesses nerve function, foot, kidneys and metabolic health. It screens for several microvascular complications at one appointment, so patients don’t need a separate visit for each test.

♦ BeyondA1C Onco: It measures sural nerve function in both legs for those undergoing chemotherapy and compares it with the patient’s own baseline, so neuropathy is graded objectively and routed to the oncologist for personalized care.

♦ BeyondA1C Dialysis: Through the test, patients who are on regular dialysis receive an IWGDF 2023 risk category from 0 to 3, so the nephrologist can initiate early intervention based on the close surveillance report.

“Sindhu Hospitals is the right place to begin in India,” said Robert Rudelius, Chief Executive Officer, MedicaMetrix. “Its clinicians and its commitment to research will show what earlier testing means for patients with diabetes, cancer and kidney disease.”

“Finding diabetic complications early should be routine care,” said Dr. B. Soma Raju,

Consultant Cardiologist and Mentor Dire tor, Sindhu Hospitals. “BeyondA1C tests will become part of our specialties, including oncology and dialysis.” “Many patients with microvascular complications have no symptoms, which is why point of care screening is critical,” noted Dr. Smitha Nalla, Consultant Endocrinologist, Sindhu Hospitals. “Screening every patient at risk lets us act sooner.”

About Sindhu Hospitals

Sindhu Hospitals is envisioned as 1500 bed multi super specialty, quaternary care hospital in Hyderabad, Telangana, India. Founded by Dr. Bandi Parthasaradhi Reddy as an initiative of Sai Sindhu Foundation and inaugurated by Prime Minister Narendra Modi in May 2026. Located in HITEC City, Sindhu Hospitals is one of India’s largest not-for-profit cancer-focused multi-super specialty hospitals.

Spread across 2.2 million square feet with 18 floors, the hospital offers comprehensive care across more than 30 specialties, supported by advanced diagnostics, state of-the-art infrastructure, cutting-edge technology, and a highly experienced team of specialists dedicated to delivering compassionate and accessible healthcare.

About BeyondA1C and MedicaMetrix, Inc.

BeyondA1C is a division of MedicaMetrix, Inc., based in Waltham, MA, USA. Its screening, diagnostic and surveillance tests for nerve injury and its diabetic and non-diabetic complications use objective, point-of-care nerve conduction testing with the FDA-cleared DPNCheck device. BeyondA1C works with hospital and lab partners globally and with the University of Sheffield

ABOUT THE AUTHOR

The Hans India